Pasar al contenido principal

Investigación y educación

Enviado por remote_content el

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia. Pharmacoecon Open.

Investigación y Educación

Gil F. 6/11/2022

Objective
The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to biologics (second-line) patients with moderate to severe active ulcerative colitis (UC).

Conclusion
The analysis suggests that in Colombia, treatment with tofacitinib for patients with moderate-to-severe UC is a cost-effective option in both lines compared with other treatment options.

Read full article

Artículos que te pueden interesar

Medicina Interna

Characteristics and Outcomes of Heart Failure Patients from a Middle- Income Country: The RECOLFACA Registry. Glob Heart.

Agosto 18, 2022

Leer más

Medicina Interna

"Clinical utility of the small bowel capsule endoscopy in the study of small bowel diseases in Colombia: Results of a national registry. Gastroenterol Hepatol."

Octubre 29, 2020

Leer más

Medicina Interna

"Registro colombiano de falla cardíaca (RECOLFACA): metodología y datos preliminares."

Julio 29, 2021

Leer más